PROMIS® and Neuro-QoLTM measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome

MLA

Glenn Phillips, et al. “PROMIS® and Neuro-QoLTM Measures Are Valid Measures of Health-Related Quality of Life among Patients with Familial Chylomicronemia Syndrome.” Expert Review of Cardiovascular Therapy, vol. 18, Apr. 2020, pp. 231–38. EBSCOhost, https://doi.org/10.1080/14779072.2020.1748011.

APA

Glenn Phillips, John Devin Peipert, Montserrat Vera-Llonch, David Cella, & Rina S. Fox. (2020). PROMIS® and Neuro-QoLTM measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy, 18, 231–238. https://doi.org/10.1080/14779072.2020.1748011

Chicago

Glenn Phillips, John Devin Peipert, Montserrat Vera-Llonch, David Cella, and Rina S. Fox. 2020. “PROMIS® and Neuro-QoLTM Measures Are Valid Measures of Health-Related Quality of Life among Patients with Familial Chylomicronemia Syndrome.” Expert Review of Cardiovascular Therapy 18 (April): 231–38. doi:10.1080/14779072.2020.1748011.